Quick Answer
Karyopharm Therapeutics Inc. reported Net Income Loss of -$196.04 million for the year ending 2025.
- Karyopharm Therapeutics Inc. showed a decrease of -156.5% in Net Income Loss from 2024 to 2025.
- This data is from Karyopharm Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 13, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), Karyopharm Therapeutics Inc.'s Net Income Loss has declined by 1,133.9%.
- Historical annual values: Fiscal year 2025: -$196.04 million | Fiscal year 2024: -$76.42 million | Fiscal year 2023: -$143.10 million | Fiscal year 2022: -$165.29 million | Fiscal year 2021: -$124.09 million | Fiscal year 2020: -$196.27 million | Fiscal year 2019: -$199.59 million | Fiscal year 2018: -$178.41 million | Fiscal year 2017: -$128.98 million | Fiscal year 2016: -$109.58 million | Fiscal year 2015: -$118.18 million | Fiscal year 2014: -$75.78 million | Fiscal year 2013: -$33.95 million | Fiscal year 2012: -$15.89 million.
- Data sourced from SEC EDGAR public filings as of June 19, 2026.
Last verified: